ADMA Biologics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Date: February 13, 2012
Event: Completion of a reverse merger between R&R Acquisition VI, Inc. (ParentCo) and ADMA Biologics, Inc. (Former ADMA). ParentCo changed its name to ADMA Biologics, Inc. and ceased to be a shell company.
Business: ADMA is a clinical-stage biotechnology company focused on developing and commercializing plasma-derived human immune globulins. Its lead product candidate, RI-001, is an Intravenous Immune Globulin (IGIV) with high levels of antibodies against Respiratory Syncytial Virus (RSV), intended for patients with Primary Immunodeficiency Disease (PIDD).
Key Financial Metrics
Capital Raise (PIPE): Gross proceeds of approximately $17.55 million from the sale of 1,828,128 shares at $9.60 per share. Net cash proceeds were approximately $15.2 million after expenses.
Historical Losses: Net loss of $5.95 million for the year ended December 31, 2010. Cumulative net loss since inception (2004) through September 30, 2011, was approximately $28.9 million.
Operating Expenses (9 months ended Sept 30, 2011): Total operating expenses were $4.5 million, including a $1.93 million loss on the sale of research and development inventory.
Debt: All senior secured convertible promissory notes were converted to equity or repaid prior to the merger. No notes remain outstanding.
Liquidity: As of September 30, 2011, the company had a working capital deficit of approximately $9.9 million. Management believes the PIPE proceeds will fund operations through the third quarter of 2013.
Material Changes vs. Prior Period
- Corporate Structure: Transitioned from a private operating company (Former ADMA) to a public reporting company via reverse merger with a shell company (ParentCo).
- Ownership: Former ADMA shareholders now hold approximately 97% of the outstanding common stock; pre-merger ParentCo shareholders hold approximately 3%.
- Management: Complete reconstitution of the Board of Directors and executive team. Adam S. Grossman appointed President and CEO.
- Accounting: The transaction is accounted for as a reverse acquisition; Former ADMA is the accounting acquirer.
- Debt Elimination: Significant reduction in debt obligations as convertible notes were converted into Series A Preferred Stock (subsequently converted to common) or repaid.
Guidance, Outlook, and Risks
Outlook: The company is preparing to submit an Investigational New Drug (IND) application for a pivotal Phase III clinical trial of RI-001. If successful, a Biologics License Application (BLA) is expected in early 2014, with potential FDA approval by year-end 2014.
Capital Needs: While current cash is projected to last until late 2013, the company may need to raise additional capital sooner if assumptions regarding expenses prove incorrect. Failure to secure financing could force a curtailment of operations.
Material Weaknesses: The independent auditor (J.H. Cohn LLP) identified material weaknesses in internal controls over financial reporting, including the financial statement closing process, segregation of duties, and accounting expertise.
Going Concern: The company has a history of losses and negative cash flows. Continued ability to operate depends on raising additional capital and successful product development.
Market Status: The company intends to qualify shares for quotation on the OTC Bulletin Board but cannot assure an active trading market will develop.
Investor Verification Checklist
- Cash Runway: Verify if the $15.2 million in net proceeds is sufficient to fund the Phase III trial and operations through Q3 2013 without further dilution.
- Internal Controls: Assess the remediation plan for the identified material weaknesses in financial reporting and the appointment of a qualified CFO/Controller.
- Regulatory Pathway: Confirm the timeline for the Phase III trial initiation and the specific FDA requirements for RI-001 approval for PIDD.
- Related Party Transactions: Review the concentration of ownership among the Grossman family, Aisling Capital, and Burrill Capital, and the terms of the shared services agreement with Areth, LLC.
- Stock Liquidity: Monitor the effectiveness of the registration statement for PIPE shares and the ability to list on the OTCBB or a national exchange.